Since 2015, anti-PD1 immunotherapy has been used as a gold standard treatment for stage IV NSCLC (as first- or second-line treatment) in combination with chemotherapy or monotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.